News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
382,781 Results
Type
Article (23743)
Company Profile (124)
Press Release (358906)
Multimedia
Podcasts (76)
Webinars (13)
Section
Business (114676)
Career Advice (962)
Deals (20586)
Drug Delivery (88)
Drug Development (51148)
Employer Resources (96)
FDA (8906)
Job Trends (8518)
News (199619)
Policy (18550)
Tag
2027 Genetown Elite (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (1346)
Academic (1)
Accelerated approval (16)
Adcomms (12)
Allergies (92)
Alliances (30231)
ALS (92)
Alzheimer's disease (824)
Antibody-drug conjugate (ADC) (133)
Approvals (9129)
Artificial intelligence (268)
Autoimmune disease (61)
Automation (18)
Bankruptcy (182)
Best Places to Work (6334)
BIOSECURE Act (11)
Biosimilars (139)
Biotechnology (49)
Bladder cancer (60)
Brain cancer (36)
Breast cancer (293)
Cancer (2109)
Cardiovascular disease (244)
Career advice (837)
Career pathing (23)
CAR-T (108)
CDC (25)
Celiac Disease (1)
Cell therapy (290)
Cervical cancer (16)
Clinical research (44431)
Collaboration (911)
Company closure (1)
Compensation (361)
Complete response letters (37)
COVID-19 (1576)
CRISPR (56)
C-suite (519)
Cystic fibrosis (73)
Data (3117)
Denatured (24)
Depression (75)
Diabetes (256)
Diagnostics (2687)
Digital health (13)
Diversity (8)
Diversity, equity & inclusion (30)
Drug discovery (141)
Drug pricing (136)
Drug shortages (25)
Duchenne muscular dystrophy (118)
Earnings (42437)
Editorial (38)
Employer branding (8)
Employer resources (88)
Events (53656)
Executive appointments (648)
FDA (10491)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (2)
Frontotemporal dementia (5)
Funding (699)
Gene editing (97)
Generative AI (24)
Gene therapy (283)
GLP-1 (639)
Government (2246)
Grass and pollen (6)
Guidances (220)
Healthcare (7919)
HIV (37)
Huntington's disease (20)
IgA nephropathy (46)
Immunology and inflammation (118)
Immuno-oncology (25)
Indications (66)
Infectious disease (1703)
Inflammatory bowel disease (114)
Inflation Reduction Act (9)
Influenza (51)
Intellectual property (122)
Interviews (148)
IPO (8178)
IRA (40)
Job creations (2421)
Job search strategy (730)
JPM (36)
Kidney cancer (10)
Labor market (47)
Layoffs (279)
Leadership (21)
Legal (4407)
Liver cancer (41)
Longevity (10)
Lung cancer (262)
Lymphoma (184)
Machine learning (19)
Management (35)
Manufacturing (485)
MASH (108)
Medical device (4137)
Medtech (4160)
Mergers & acquisitions (12981)
Metabolic disorders (714)
Multiple sclerosis (101)
NASH (19)
Neurodegenerative disease (134)
Neuropsychiatric disorders (45)
Neuroscience (1479)
Neurotech (1)
NextGen: Class of 2026 (3118)
Non-profit (1995)
Now hiring (20)
Obesity (343)
Opinion (174)
Ovarian cancer (73)
Pain (135)
Pancreatic cancer (81)
Parkinson's disease (138)
Partnered (21)
Patents (235)
Patient recruitment (194)
Peanut (27)
People (38592)
Pharmaceutical (66)
Pharmacy benefit managers (21)
Phase 1 (11530)
Phase 2 (19195)
Phase 3 (16725)
Pipeline (2631)
Policy (189)
Postmarket research (1819)
Preclinical (4630)
Press Release (48)
Prostate cancer (131)
Psychedelics (27)
Radiopharmaceuticals (163)
Rare diseases (478)
Real estate (3418)
Recruiting (35)
Regulatory (14292)
Reports (22)
Research institute (1303)
Resumes & cover letters (123)
Rett syndrome (6)
RNA editing (7)
RSV (41)
Schizophrenia (87)
Series A (134)
Series B (89)
Service/supplier (4)
Sickle cell disease (60)
Special edition (11)
Spinal muscular atrophy (112)
Sponsored (15)
Startups (2269)
State (2)
Stomach cancer (8)
Supply chain (60)
Tariffs (73)
The Weekly (50)
Vaccines (541)
Venture capital (50)
Weight loss (230)
Women's health (42)
Worklife (10)
Date
Last 7 days (275)
Last 30 days (972)
Last 365 days (14751)
2026 (1308)
2025 (15127)
2024 (17689)
2023 (20082)
2022 (27230)
2021 (29114)
2020 (27971)
2019 (24070)
2018 (18623)
2017 (19167)
2016 (18476)
2015 (21949)
2014 (16755)
2013 (13797)
2012 (14962)
2011 (15671)
2010 (14042)
Location
Africa (471)
Alabama (26)
Alaska (4)
Arizona (118)
Arkansas (4)
Asia (27440)
Australia (4120)
California (4699)
Canada (1801)
China (707)
Colorado (194)
Connecticut (186)
Delaware (175)
Europe (59207)
Florida (840)
Georgia (161)
Hawaii (1)
Idaho (25)
Illinois (488)
India (53)
Indiana (308)
Iowa (4)
Japan (310)
Kansas (83)
Kentucky (26)
Louisiana (13)
Maine (14)
Maryland (659)
Massachusetts (3558)
Michigan (85)
Minnesota (279)
Mississippi (1)
Missouri (59)
Montana (11)
Nebraska (12)
Nevada (42)
New Hampshire (17)
New Jersey (1751)
New Mexico (14)
New York (1395)
North Carolina (781)
North Dakota (2)
Northern California (2200)
Ohio (141)
Oklahoma (7)
Oregon (21)
Pennsylvania (1052)
Puerto Rico (13)
Rhode Island (19)
South America (715)
South Carolina (19)
Southern California (1971)
Tennessee (74)
Texas (671)
United States (18176)
Utah (103)
Virginia (181)
Washington D.C. (47)
Washington State (397)
West Virginia (1)
Wisconsin (49)
Wyoming (2)
382,781 Results for "simcere pharmaceutical group".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Inflammatory bowel disease
Boehringer Commits up to $1.26B in IBD Pact With China’s Simcere
The cornerstone of the deal is SIM0709, which Simcere designed to target both TL1A and IL-23, crucial players in facilitating inflammation. Boehringer Ingelheim will advance the asset for inflammatory bowel diseases.
January 27, 2026
·
2 min read
·
Tristan Manalac
Antibody-drug conjugate (ADC)
NextCure Joins China-ADC Gold Rush with $745M Simcere Deal
The deal gets NextCure the rights to Simcere’s novel ADC for solid tumors outside of China.
June 16, 2025
·
1 min read
·
Dan Samorodnitsky
Press Releases
Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease
January 27, 2026
·
3 min read
Press Releases
Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate
December 22, 2025
·
7 min read
Press Releases
Simcere’s IL-2 Mutant Fusion Protein SIM0278 Entered Phase II Clinical Trial Stage
November 10, 2025
·
3 min read
Press Releases
Global expansion of Idorsia’s QUVIVIQ continues as Simcere launches in China
September 22, 2025
·
6 min read
Policy
Simcere Zaiming Announce Approval of Cetuximab Beta in China by the NMPA
On June 25, 2024, Simcere Zaiming, an innovative oncology company and a subsidiary of Simcere Pharmaceutical Group, announced that Enlituo®, a new generation anti-epidermal growth factor receptor antibody drug developed in collaboration with Mabpharm Limited, has recently received approval from the China National Medical Administration for marketing.
June 26, 2024
·
4 min read
Press Releases
Idorsia’s QUVIVIQ expands into China as Simcere receives NDA approval – Idorsia and Simcere update their licensing agreement
June 23, 2025
·
4 min read
Press Releases
NextCure and Simcere Zaiming Announce Expansion of Ongoing Phase 1 Trial of SIM0505 (CDH6 ADC) into the United States
October 17, 2025
·
5 min read
Genetown
Simcere Pharmaceutical Group Announces Sponsored Research Agreement with Boston-based Mass General Brigham
Simcere Pharmaceutical Group Limited announced a Sponsored Research Agreement with Mass General Brigham.
June 12, 2023
·
5 min read
1 of 38,279
Next
